CYP2C19 and diabetes mellitus: The aim of this study was to develop a PBPK-PD model considering CYP2C19 polymorphisms to simultaneously predict the pharmacokinetics of CLOP, CLOP-AM as well as the IPA following oral administration to CAD patients with or without DM.